Seres (MCRB) Stock: Here’s What You Need To Know

Seres Therapeutics (NASDAQ:MCRB) On Friday, Seres Therapeutics stock plummeted by 70% after the company reported that it had failed mid-stage trial in patients with Clostridium difficile infection or C. diff. The company has a big pipeline, but the problem is that the study that failed was the lead drug candidate. Thus, the reason why the … Read more